Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Spriggs

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Journal of the National Cancer Institute|September 7, 1988
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic studyD R Spriggs, M L Sherman, H Michie, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 15, 2005
Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancerJ J Kavanagh, D M Gershenson, H Choi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1982
Identification of idiotypic receptors on reovirus-specific cytolytic T cellsH C Ertl, M I Greene, J H Noseworthy, et al.
Investigational New Drugs|November 11, 1999
Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812)K D Tutsch, R Z Arzoomanian, D Alberti, et al.
Lancet (London, England)|August 10, 1999
Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trialD I Bernstein, D A Sack, E Rothstein, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusionsH Bailey, G Wilding, K D Tutsch, et al.
Seminars in Oncology|February 1, 1997
Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancerD W Fennelly, C Aghajanian, F Shapiro, et al.
Vaccine|June 2, 1998
Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12D I Bernstein, V E Smith, J R Sherwood, et al.
The New England Journal of Medicine|June 9, 1988
Detection of circulating tumor necrosis factor after endotoxin administrationH R Michie, K R Manogue, D R Spriggs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathioneH H Bailey, R T Mulcahy, K D Tutsch, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Journal of the National Cancer Institute|September 7, 1988
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic studyD R Spriggs, M L Sherman, H Michie, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 15, 2005
Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancerJ J Kavanagh, D M Gershenson, H Choi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1982
Identification of idiotypic receptors on reovirus-specific cytolytic T cellsH C Ertl, M I Greene, J H Noseworthy, et al.
Investigational New Drugs|November 11, 1999
Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812)K D Tutsch, R Z Arzoomanian, D Alberti, et al.
Lancet (London, England)|August 10, 1999
Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trialD I Bernstein, D A Sack, E Rothstein, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusionsH Bailey, G Wilding, K D Tutsch, et al.
Seminars in Oncology|February 1, 1997
Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancerD W Fennelly, C Aghajanian, F Shapiro, et al.
Vaccine|June 2, 1998
Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12D I Bernstein, V E Smith, J R Sherwood, et al.
The New England Journal of Medicine|June 9, 1988
Detection of circulating tumor necrosis factor after endotoxin administrationH R Michie, K R Manogue, D R Spriggs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathioneH H Bailey, R T Mulcahy, K D Tutsch, et al.
Pageof 10